Metagenomi, Inc. Common Stock

Price Chart

Risk-Adjusted Performance

Metagenomi, Inc. Common Stock (MGX) Price Performance

Metagenomi, Inc. Common Stock (MGX) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $1.37, down 3.52% from the previous close.

Over the past year, MGX has traded between a low of $1.26 and a high of $3.35. The stock has lost 13.8% over this period. It is currently 59.1% below its 52-week high.

Metagenomi, Inc. Common Stock has a market capitalization of $53.42M.

About Metagenomi, Inc. Common Stock

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.